Prognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma
Authors:
- Manuel Díez-AlonsoMDManuel Díez-Alonso
- Fernando Mendoza-MorenoFMFernando Mendoza-Moreno
- Remedios Gómez-SanzRGRemedios Gómez-Sanz
- Belén Matías-GarcíaBMBelén Matías-García
- Enrique Ovejero-MerinoEOEnrique Ovejero-Merino
- Raquel MolinaRMRaquel Molina
- Sonia Soto-SchütteSSSonia Soto-Schütte
- Alberto San JuanAJAlberto San Juan
- Alberto Gutierrez-CalvoAGAlberto Gutierrez-Calvo
Open Access
- 13 September 2021
- journal article
- review article
- Published by Hindawi Limited in International Journal of Surgical Oncology
- Vol. 2021, 1-9
Abstract
Objective. The main objective of the study was to determine the effect of the presence of mutation in the KRAS gene on the survival in patients with colorectal cancer (CRC) and peritoneal metastases (PM). Materials and Methods. A retrospective cohort study was performed. Patients diagnosed with CRC with synchronous or metachronous PM between January 2006 and December 2019 were included. Data on the histopathological, clinical, and treatment factors were collected. The effect of each variable on survival was evaluated by Cox regression. Results. A total of 149 patients were included (64 women (43%) and 85 men (57%); mean age, 63 years). The long-term survival rate at 36 months was 24% (median, 21 months). KRAS mutation was detected in 75 patients (50.3%). Kaplan–Meier analysis estimated that likelihood of survival was higher in patients with wild-type KRAS tumours (35%) than in mutated-type KRAS (14%) (median: 28 vs. 15, respectively) ( P = 0.001 ). Within the categories into which the peritoneal cancer index (PCI) was classified, survival at 36 months depended on the KRAS status. Survival in wild-type KRAS tumours with PCI 1–10 was 71% and with PCI 11–20 was 26%, while in mutant-type KRAS tumours, survival was 41% and 4%, respectively ( P = 0.025 ). In the multiple regression analysis, the KRAS mutation was revealed to have an independent prognostic value (HR: 2.144; 95% CI: 1.342–3.424). Conclusion. The mutational status of the KRAS gene has demonstrated a strong association with survival and prognostic utility in patients with CRC with PM.Keywords
This publication has 24 references indexed in Scilit:
- Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomesThe American Journal of Surgery, 2017
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnnals of Oncology, 2016
- Development of a Prognostic Nomogram for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPECAnnals of Surgical Oncology, 2016
- Patterns of metachronous metastases after curative treatment of colorectal cancerCancer Epidemiology, 2014
- The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal CarcinomatosisAnnals of Surgical Oncology, 2014
- Individualized prediction of risk of metachronous peritoneal carcinomatosis from colorectal cancerColorectal Disease, 2014
- Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancerBritish Journal of Surgery, 2012
- Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population‐based studyInternational Journal of Cancer, 2010
- KRAS Status in Patients With Colorectal Cancer Peritoneal Carcinomatosis and Its Impact on OutcomeAmerican Journal of Clinical Oncology, 2010
- Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741Journal of Clinical Oncology, 2008